Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis

Viral infections cause many severe human diseases, being responsible for remarkably high mortality rates. In this sense, both the academy and the pharmaceutical industry are continuously searching for new compounds with antiviral activity, and in addition, face the challenge of developing greener an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Everton M. da Silva, Hérika D. A. Vidal, Arlene G. Corrêa
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	antivirals green chemistry selectivity asymmetric synthesis organocatalysis Medicine R Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/329eb120dc67468ea2c2713f848ed14d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:329eb120dc67468ea2c2713f848ed14d
record_format	dspace
spelling	oai:doaj.org-article:329eb120dc67468ea2c2713f848ed14d2021-11-25T18:39:32ZAdvances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis10.3390/ph141111251424-8247https://doaj.org/article/329eb120dc67468ea2c2713f848ed14d2021-11-01T00:00:00Zhttps://www.mdpi.com/1424-8247/14/11/1125https://doaj.org/toc/1424-8247Viral infections cause many severe human diseases, being responsible for remarkably high mortality rates. In this sense, both the academy and the pharmaceutical industry are continuously searching for new compounds with antiviral activity, and in addition, face the challenge of developing greener and more efficient methods to synthesize these compounds. This becomes even more important with drugs possessing stereogenic centers as highly enantioselective processes are required. In this minireview, the advances achieved to improve synthetic routes efficiency and sustainability of important commercially antiviral chiral drugs are discussed, highlighting the use of organocatalytic methods.Everton M. da SilvaHérika D. A. VidalArlene G. CorrêaMDPI AGarticleantiviralsgreen chemistryselectivityasymmetric synthesisorganocatalysisMedicineRPharmacy and materia medicaRS1-441ENPharmaceuticals, Vol 14, Iss 1125, p 1125 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	antivirals green chemistry selectivity asymmetric synthesis organocatalysis Medicine R Pharmacy and materia medica RS1-441
spellingShingle	antivirals green chemistry selectivity asymmetric synthesis organocatalysis Medicine R Pharmacy and materia medica RS1-441 Everton M. da Silva Hérika D. A. Vidal Arlene G. Corrêa Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis
description	Viral infections cause many severe human diseases, being responsible for remarkably high mortality rates. In this sense, both the academy and the pharmaceutical industry are continuously searching for new compounds with antiviral activity, and in addition, face the challenge of developing greener and more efficient methods to synthesize these compounds. This becomes even more important with drugs possessing stereogenic centers as highly enantioselective processes are required. In this minireview, the advances achieved to improve synthetic routes efficiency and sustainability of important commercially antiviral chiral drugs are discussed, highlighting the use of organocatalytic methods.
format	article
author	Everton M. da Silva Hérika D. A. Vidal Arlene G. Corrêa
author_facet	Everton M. da Silva Hérika D. A. Vidal Arlene G. Corrêa
author_sort	Everton M. da Silva
title	Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis
title_short	Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis
title_full	Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis
title_fullStr	Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis
title_full_unstemmed	Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis
title_sort	advances on greener asymmetric synthesis of antiviral drugs via organocatalysis
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/329eb120dc67468ea2c2713f848ed14d
work_keys_str_mv	AT evertonmdasilva advancesongreenerasymmetricsynthesisofantiviraldrugsviaorganocatalysis AT herikadavidal advancesongreenerasymmetricsynthesisofantiviraldrugsviaorganocatalysis AT arlenegcorrea advancesongreenerasymmetricsynthesisofantiviraldrugsviaorganocatalysis
_version_	1718410825516974080

Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis

Ejemplares similares